

33. The composition according to Claim 22 wherein the liposomes are in dehydrated form.

34. A method of preparing a composition according to Claim 22 comprising removing solvent from a solution of the lipid mixture in an organic solvent to give a lipid residue, mixing the lipid residue with an aqueous medium containing an α -interferon hybrid, agitating the resulting mixture to obtain an aqueous suspension of liposomes containing entrapped α -interferon hybrid and extruding the suspension through one or more membrane filters.


REMARKS

By this Preliminary Amendment, applicants have cancelled Claims 1-21 and added new Claims 22-34. Support for new Claims 22-34 is found in the cancelled claims. More specifically, applicants have included a phase transition temperature limitation for the lipid mixture, as found in the specification on page 2, lines 8-9, and specified that the charged phospholipid be negatively charged, as found in the specification on page 3, line 1.

Applicants respectfully request that the Examiner enter applicants' Preliminary Amendment.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6950


John D. Thallemer
Attorney for Applicants
Reg. No. 34,940

Date: October 24, 2001